玉溪市做人流那家医院好玉溪做人流的医院哪好,玉溪医院无痛人流价格,玉溪做流产手哪个医院比较好点,玉溪做人流一般需多少钱,玉溪哪个医院做人流安全,玉溪市无痛人流哪里做,玉溪去哪里做人流

BRUSSELS, April 29 (Xinhua) -- As a 2004 European Union (EU) directive on herbal medicine is to be fully implemented on May 1, herbal medicinal products without a license will no longer be allowed in the EU market, the European Commission said in a press release Friday.The Traditional Herbal Medicinal Products Directive, adopted by the EU member states in 2004, introduced a so-called simplified registration procedure with a seven-year transition period for traditional herbal medicinal products to obtain a medicine license.As the transition period is to expire on Saturday, herbal medicinal products from home and abroad, most of which have been sold as food supplements for decades, need to be medically registered or authorized by EU governments in order to remain in the market after May 1.Instead of going through safety tests and clinical trials as regular chemical drugs, applicants are required by the directive to provide documents showing the herbal medicinal product is not harmful in the specified condition of use, as well as evidence that the product at least has a 30-year history of safe use, including 15 years in the EU.However, a wide range of eligibility and technical challenges along with prohibitive costs have so far prevented both local and outside herbal medicinal products from being granted the license.Only a small proportion of indigenous herbal medicinal products have been approved for registration while not a single Chinese or Indian traditional herbal medicinal products have been licensed.Lack of pan-European rules, EU member states had adopted different approaches to herbal medicine, thus creating a "state of anarchy" in the markets despite the fact that indigenous herbs had a 700-year history of use in Europe.Although the directive was intended to harmonize rules of member states and build a level-playing field across the EU, critics argued that the directive may fall short of the aim and create more chaos and uncertainties for the industry.DRAWBACKSThe directive has been under attack for being neither "adequate " nor "appropriate" due to its high registration cost for a single product and its lack of consideration about the Chinese and Indian traditional herbal medicine.Chris Dhaenens, a licensed herbalist in Belgium and a shareholder of a medium-sized herbal importing company doing business with China and ten European countries, said the directive was only appropriate for companies carrying a few products and who could afford the registration costs."It is simply inaccessible to most players distributing high- quality Chinese or Indian herbal products in Europe," he said, adding that the registration fee for a single product could be as high as 150,000 euros.The Alliance for Natural Health, a British-based group representing herbal practitioners, estimated the cost of obtaining a license at between 80,000 and 120,000 pounds (90,000 to 135,000 U.S. dollars) per herb.Dhaenens, who is also the president of the European Benefyt Foundation, a leading traditional medicine group in Europe, argued that the directive only tried to regulate herbal products instead of its practitioners and the whole herbal system, as well as fell short to take the Chinese and Indian traditional medicine into full consideration.Even the European Commission had admitted that the directive was not fit for the registration of Chinese and Indian medicine in an earlier exchange with the European Medicine Agency in Dec. 2008, Dhaenens revealed in an exclusive interview with Xinhua."But they had no money or time to work out an alternative, and so it was left to the member states," he said.

BEIJING, March 7 (Xinhua) -- The Chinese currency Renminbi (RMB), or the yuan, on Monday strengthened to an all-time high of 6.5651 per U.S. dollar, according to the China Foreign Exchange Trading System.Monday's central parity rate of the RMB against U.S. dollar was 20 basis points lower than the previous record of 6.5671 set on last Friday.The yuan has appreciated 3.84 percent since June 19 last year when the People's Bank of China, the central bank, announced it would further reform the exchange rate formation mechanism to improve its flexibility.On China's foreign exchange spot market, the yuan can rise or fall 0.5 percent from the central parity rate each trading day.The central parity rate of the RMB against the U.S. dollar is based on a weighted average of prices before the opening of the market for each business day.

BEIJING, Feb. 10 (Xinhua) -- Chinese researchers have made significant progress in developing key technologies for natural disaster early warning systems and emergency relief, according to the Ministry of Science and Technology (MST).The four-year project, "Research on Key Technologies for Geological Disasters Monitoring, Early Warning and Emergency Relief," was initiated in 2006 with support from China's top-level government scientific research funding program.Scientists involved in the project had made remarkable technological progress in four fields, namely natural disaster recognition in earlier stage, monitoring and early warning, risks assessment and emergency relief, the MST said in a statement on its website.As part of the project, rain-triggered landslide monitoring and early warning systems have been established around Mount Ailao in southwest China's Yunnan Province and in the southeastern area of east China's Fujian Province.A natural disasters monitoring system has been developed by Chinese scientific workers using optical fiber technologies. This system with Chinese intellectual property has been put into use in areas, including the the reservoir region of the Three Gorges Project on the middle reaches of the Yangtze River.According to the MST, the research project also provided substantial technological support in assessment of disasters and relevant relief during China's responses to the Wenchuan earthquake in May 2008 and the massive mudslide in Zhouqu of Gansu last August.

LOS ANGELES, April 27 (Xinhua) -- Air pollution poses a threat to the health of about 154 million Americans -- or more than half of the U.S. population, the American Lung Association (ALA) said on Wednesday.The air is so polluted in some areas that it is often dangerous to breathe, the ALA said in its annual report on air quality across the United States.About 48 percent of U.S. residents live in counties where smog (ozone) is too high, 20 percent live in areas where there are too many short-term spikes in pollution and six percent live in areas with harmful year-round soot (particle pollution), said the report.About 17 million Americans live in areas afflicted by all three air pollution hazards, the report noted.The report listed California as the most polluted state, where people are breathing some of the worst air.Compared with other states, California has more polluted places, including Los Angeles, Long Beach, Riverside, Bakersfield and Fresno, the report said.Honolulu in Hawaii and Santa Fe-Espanola in New Mexico are the only two cities in the nation that had no days in which smog and soot levels reached unhealthy ranges, making them the cleanest cities in the nation, said the report.Research suggests air pollution threatens human health -- and not just the lungs.Small particles of pollution can lodge deep in the lungs, triggering an inflammatory process that, over time, can spread elsewhere in the body and damage blood vessels and the heart, according to Dr. Norman Edelman, the ALA's chief medical officer.On days in which smog levels spike, there's an increase in hospital admissions for respiratory illnesses, heart attacks and stroke in the two or three days following it, said Michael Jerrett, a professor of environmental health sciences at University of California, Berkeley's School of Public Health.In addition to posing both long-term and short-term risks, pollution can also contribute to low birth weights, diabetes, cardiovascular disease, heart attack, stroke and, ultimately, shorter life spans, he warned.

WASHINGTON, May 11 (Xinhua) -- Johns Hopkins University researchers have demonstrated that human liver cells derived from adult cells coaxed into an embryonic state can engraft and begin regenerating liver tissue in mice with chronic liver damage.The work, published Wednesday in the journal Science Translational Medicine, suggests that liver cells derived from so- called "induced-pluripotent stem cells (iPSCs)" could one day be used as an alternative to liver transplant in patients with serious liver diseases, bypassing long waiting lists for organs and concerns about immune system rejection of donated tissue."Our findings provide a foundation for producing functional liver cells for patients who suffer liver diseases and are in need of transplantation," says Yoon-Young Jang, assistant professor of oncology at the Johns Hopkins Kimmel Cancer Center. "iPSC-derived liver cells not only can be generated in large amounts, but also can be tailored to each patient, preventing immune-rejection problems associated with liver transplants from unmatched donors or embryonic stem cells." A microsopic view shows human embryonic stem cells in various stages of differentiation into liver cells in this photo taken at Stanford University and released by the California Institute for Regenerative Medicine, March 9, 2009iPSCs are made from adult cells that have been genetically reprogrammed to revert to an embryonic stem cell-like state, with the ability to transform into different cell types. Human iPSCs can be generated from various tissues, including skin, blood and liver cells.Although the liver can regenerate in the body, end-stage liver failure caused by diseases like cirrhosis and cancers eventually destroy the liver's regenerative ability, Jang says. Currently, the only option for those patients is to receive a liver organ or liver cell transplant, a supply problem given the severe shortage of donor liver tissue for transplantation. In addition, mature liver cells and adult liver stem cells are difficult to isolate or grow in the laboratory, she says. By contrast, iPSCs can be made from a tiny amount of many kinds of tissue; and the embryonic stem- like iPSCs can grow in laboratory cultures indefinitely.For the study, Jang and colleagues generated human iPSCs from a variety of adult human cells, including liver cells, fibroblasts ( connective tissue cells), bone marrow stem cells and skin cells. They found that though the iPSCs overall were molecularly similar to each other and to embryonic stem cells, they retained a distinct molecular "signature" inherited from the cell of origin.